The American Medicines Agency (FDA) has stopped a dozen products from the Aargau company Similisan (archives). © KEYSTONE/GAETAN BALLY
Published on 09/23/2023
The Aargau manufacturer of homeopathic medicines Similasan specifies that the ban on the import of its eye drops decreed by the United States has no impact on the Swiss market. There is no risk to customers and patients, the company says.
The United States Medicines Agency (FDA) has tightened its requirements for several eye drop manufacturers, including all Similasan eye drops. This decision only concerns the American market, a company spokesperson told Keystone-ATS on Saturday.
Similasan specifies in a press release that the FDA’s criticisms mainly relate to the description of the product on the packaging. There is no danger in using the drops. The Aargau company says it is working closely with the American authorities to meet the new requirements and be able to export again.
The FDA mainly has manufacturers of homeopathic products in its crosshairs. Various products from companies competing with Similasan caused adverse effects in American patients earlier this year, problems from which the Swiss company completely distances itself.
Since its establishment in the United States in 1987, the company has sold more than 100 million doses of eye drops.
ats
2023-09-23 14:05:12
#Similasan #reassures #problems #United #States
